文献速递艾滋病与性传播感染病毒性肝炎

糖尿病与HIV合并MASLD成人显著肝纤维化风险:前瞻性队列研究

Diabetes and risk of significant fibrosis in adults with HIV and metabolic dysfunction-associated steatotic liver disease: a prospective cohort study.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

该前瞻性队列研究纳入345例HIV合并代谢功能障碍相关脂肪性肝病(MASLD)成人,随访中位4年,评估基线2型糖尿病(T2DM)与显著肝纤维化(LSM≥7.5 kPa)风险的关系。结果显示基线T2DM患者显著肝纤维化风险较无T2DM者高3倍以上(aIRR 3.35,95%CI 1.67-6.75),而肝硬度随时间变化与基线T2DM无关。

要点

  • HIV合并MASLD者中,基线T2DM显著增加显著肝纤维化风险(aIRR 3.35)。
  • 随访4年肝硬度均值轻微下降,变化与基线T2DM无显著交互。
  • 时间更新BMI每增加1 kg/m²与显著肝纤维化风险独立相关(aIRR 1.10)。

核心结论

  • HIV合并MASLD成人中,基线T2DM与显著肝纤维化风险升高独立相关,尽管肝硬度在4年随访中保持稳定。

研究设计与样本

  • 前瞻性队列研究,纳入345例HIV合并MASLD且至少两次VCTE测量的成人,随访中位4年。

主要发现

  • 345例中97例(28%)基线有T2DM,35%为女性。
  • 调整后肝硬度均值每年下降0.15 kPa(95%CI -0.28至-0.01),变化与基线T2DM无关(P交互=0.40)。
  • 基线无肝纤维化的253例中,显著肝纤维化发生率为3.89/100人年(95%CI 2.79-5.41)。
  • 基线T2DM者显著肝纤维化风险为无T2DM者的3.35倍(aIRR 3.35,95%CI 1.67-6.75)。
  • 时间更新BMI每增加1 kg/m²,显著肝纤维化风险aIRR为1.10(95%CI 1.03-1.18)。

关键数值与推荐

  • 显著肝纤维化定义为肝硬度测量值(LSM)≥7.5 kPa。
  • MASLD诊断通过振动控制瞬时弹性成像(VCTE)进行。

临床怎么用

  • 对HIV合并MASLD且基线有T2DM的患者,应优先加强肝纤维化监测与治疗干预。
  • 管理过程中关注体重变化,BMI升高与显著肝纤维化风险增加相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Limited data exist on whether the presence of type-2 diabetes mellitus (T2DM) increases the risk of significant liver fibrosis (LF) among people with HIV (PWH) and metabolic dysfunction-associated steatotic liver disease (MASLD). This study examined liver stiffness progression and significant LF risk according to T2DM status in PWH with MALSD (PWH-MASLD) diagnosed via vibration-controlled transient elastography (VCTE). METHODS: PWH who had MASLD and had ≥2 VCTE measurements during the follow-up (median duration 4 years) were included. Change in liver stiffness measurement (LSM) from baseline (ΔLSM) was evaluated using a linear mixed-effects model. Multivariable Poisson regression was used to evaluate association between baseline T2DM and significant LF incidence (LSM ≥7.5 kPa). RESULTS: Among 345 PWH with MASLD (35% female), 97 (28%) had T2DM at baseline. In adjusted analysis, LSM declined modestly over time [mean -0.15 kPa/year (95% CI -0.28, -0.01)]. The ΔLSM over time was not associated with baseline T2DM (Pinteraction = 0.40). Among 253 PWH-MASLD without LF at baseline, the incidence of LF was 3.89 [95% CI 2.79-5.41]/100 person-years. Participants with baseline T2DM had a >3-fold higher risk of significant LF compared with those without T2DM [adjusted incidence risk ratio (aIRR): 3.35, 95% CI: 1.67-6.75). Time-updated BMI (per kg/m2 increase) was also associated with significant LF (aIRR, 1.10, 95% CI 1.03-1.18). CONCLUSIONS: Despite stable LSM over 4 years of follow-up, PWH with MASLD and T2DM have a significantly higher risk of LF. Prioritizing this population for intensive monitoring and treatments interventions may help mitigate liver disease progression.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Han WM, Apornpong T, Chuaypen N, et al. Diabetes and risk of significant fibrosis in adults with HIV and metabolic dysfunction-associated steatotic liver disease: a prospective cohort study. J Antimicrob Chemother. 2026. PMID: 41710964. doi:10.1093/jac/dkag053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。